Updates in the Treatment of Renal Cell Carcinoma: Highlights from IKCS and ESMO 2022

home / readout-360 / updates-in-the-treatment-of-renal-cell-carcinoma-highlights-from-ikcs-and-esmo-2022

A panel of experts review key data updates in renal cell carcinoma (RCC) from the International Kidney Cancer Association (IKCS) and European Society for Medical Oncology (ESMO) 2022 meetings and discuss how recent clinical trials are shaping the treatment of clear cell and non-clear cell RCC in clinical practice.

CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes

EP. 1: CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
February 13th 2023

Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.

CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings

EP. 2: CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
February 13th 2023

Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.

Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy

EP. 3: Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
February 23rd 2023

Moshe Ornstein, MD, explains which patients with RCC he observes for progression prior to systemic therapy.

Impact of the CLEAR Trial Data Updates in Clinical Practice

EP. 4: Impact of the CLEAR Trial Data Updates in Clinical Practice

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
February 23rd 2023

The panel discusses the potential impact of updated data from the CLEAR trial on the treatment of patients with advanced RCC in clinical practice.

Approaches to the Frontline Treatment of Advanced Kidney Cancer

EP. 5: Approaches to the Frontline Treatment of Advanced Kidney Cancer

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
February 23rd 2023

Experts summarize their most common frontline treatment approaches to advanced RCC.

Switching a Patient with Advanced RCC Between IO + TKI and IO + IO Combination Regimens

EP. 6: Switching a Patient with Advanced RCC Between IO + TKI and IO + IO Combination Regimens

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
March 9th 2023

The panel discusses which patients they would consider switching between immunotherapy combination treatments.

Approaches to Dosing TKIs in Patients with Advanced RCC

EP. 7: Approaches to Dosing TKIs in Patients with Advanced RCC

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
March 9th 2023

Best approaches to dosing and dose-reduction of TKI agents in the treatment of advanced RCC.

COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC

EP. 8: COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
March 13th 2023

The doctors review data from the COSMIC-313 trial investigating a frontline triplet therapy for advanced RCC.

Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC

EP. 9: Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
March 13th 2023

The panel continues their discussion of investigational triplet therapies in frontline RCC treatment.

Clinical Trials in Adjuvant IO Therapy for RCC

EP. 10: Clinical Trials in Adjuvant IO Therapy for RCC

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
March 20th 2023

Tian Zhang, MD, explains whether recent data from ESMO 2022 has changed their approach to adjuvant immune therapy in advanced RCC.

Disease Progression After Adjuvant Pembrolizumab Therapy for RCC

EP. 11: Disease Progression After Adjuvant Pembrolizumab Therapy for RCC

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
March 20th 2023

The panel shares how they would treat a patient with advanced RCC after disease progression on adjuvant pembrolizumab.

Frontline Therapy for Non-Clear Cell RCC

EP. 12: Frontline Therapy for Non-Clear Cell RCC

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA
March 20th 2023

The panel wraps up their discussion with a review of how they would approach treating frontline non-clear cell RCC.

Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

EP. 13: Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

ONCOLOGY Staff
May 13th 2023

A panel of experts discuss the updated results of the phase 3 CLEAR trial presented at the 2022 International Kidney Cancer Symposium.